Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

Adamas Pharmaceuticals Inc (NASDAQ: ADMS) has announced the publication of pooled analyses of Gocovri (amantadine) from pivotal studies in Parkinson's disease. Data were published in the peer-reviewed journal Frontiers in Neurology.

Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson's disease” in the peer-reviewed journal Frontiers in Neurology. GOCOVRI® (amantadine) extend

Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson's disease

Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, plus the exercise in full by the underwriters of their option to purchase an additional 1,875,000 shares, at a price to the public of $4.40 per share. T

Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underw

Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15

Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering

Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript

Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).

Adamas Pharmaceuticals: Q4 Earnings Insights

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020, and recent corporate highlights. “We are excited with the opportunities ahead of us, including the continued growth of GOCOVRI which is now the first and only medication approved to tr

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results

Adamas Pharmaceuticals (NASDAQ:ADMS) announces its next round of earnings this Tuesday, February 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

A Preview Of Adamas Pharmaceuticals's Earnings

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences: 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET (10:40 a.m. PT) Cowen 41st Annual Healthcare Conference

Adamas to Present at Upcoming Healthcare Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing 1-877-407-9716 for

Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunc

Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson's Disease Patients Experiencing OFF Episodes

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus's Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and

Adamas Announces Settlement of Patent Litigation with Zydus

-- Total revenues expected to be $20.8 million for fourth quarter 2020  and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020  and $71.2 million for full year 2020 --

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021.

Adamas to Present at Upcoming ICR Conference

Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition

Adamas Completes Acquisition of OSMOLEX ER®

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.

Adamas to Present at Upcoming H.C. Wainwright Conference

Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company

Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners

As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER®

Adamas Announces Agreement to Settle Patent Litigation with Osmotica

EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, is scheduled to present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 am Eastern Time (8:45 am Pacific).

Adamas to Present at Upcoming Evercore ISI Conference

EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia, Cavion, Teva, Pfizer, Allergan, and Biogen. Additionally, Adamas announced the retirement of Ivan Lieberburg, MD, PhD from the Adamas board.

Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020.

Adamas to Present at Upcoming Piper Sandler Conference

Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhythm for GOCOVRI and the commericial numbers continue to improve. In addition,i t is now collecting royalties for NAMZARIC.

News for Adamas Pharmaceuticals Stock (ADMS)